Kevin F. Boehnke and Tristin Smith are with the Chronic Pain and Fatigue Research Center and Michigan Psychedelic Center within the Anesthesiology Department at the University of Michigan Medical School, Ann Arbor. Rachel Sinclair, Douglas R. Roehler, and Brooke Hoots are with the Cannabis Strategy Unit, Centers for Disease Control and Prevention, Atlanta, GA. Felicia Gordon is a BS candidate at the Chronic Pain and Fatigue Research Center within the Anesthesiology Department at the University of Michigan Medical School. Douglas R. Roehler and Brooke Hoots were also Guest Editors for this supplement issue.
Am J Public Health. 2024 Nov;114(S8):S685-S693. doi: 10.2105/AJPH.2024.307728.
To investigate characteristics of data reported in US medical cannabis registries across states. Data included 2021 medical cannabis registry reports from 34 states, Puerto Rico, and the District of Columbia (hereafter, states) with active medical cannabis programs. The data from the reports were manually coded into domains and subcategories, including information related to patients (e.g., number, demographics), authorizing clinicians, sales (e.g., content, revenue), license tracking, and health and safety outcomes. Among 36 states, 97% reported total patient number and 75% reported number of authorizing clinicians. Least reported subcategories included patient race/ethnicity (8%), adverse events (11%), therapeutic benefits (6%), and product recalls (6%). States that recently legalized medical cannabis (2013-2018) reported a higher number of subcategories overall, with a median of 11 versus 8 for early adopting states (1996-2012). More medical-use states reported data on authorizing clinicians compared with nonmedical adult-use states but were otherwise similar. Medical cannabis state registries generally reported data on consumers, clinicians, and sales rather than health and safety outcomes. More comprehensive and uniform medical cannabis public health surveillance is needed. (. 2024;114(S8):S685-S693. https://doi.org/10.2105/AJPH.2024.307728).
调查美国各州医疗大麻注册中心报告数据的特点。数据包括来自 34 个州、波多黎各和美属维尔京群岛（以下简称各州）的 2021 年医疗大麻注册报告，这些州都有活跃的医疗大麻项目。报告中的数据被手动编码到各个领域和子类别中，包括与患者相关的信息（例如患者数量、人口统计学特征）、授权临床医生、销售情况（例如产品内容、收入）、许可证跟踪以及健康和安全结果。在 36 个州中，有 97%的州报告了总患者数量，75%的州报告了授权临床医生的数量。报告中最少涉及的子类别包括患者种族/族裔（8%）、不良事件（11%）、治疗效益（6%）和产品召回（6%）。最近将医疗大麻合法化的州（2013-2018 年）总体上报告了更多的子类别，中位数为 11 个，而早期采用州（1996-2012 年）的中位数为 8 个。更多的医用大麻州报告了授权临床医生的数据，而非医用成人使用州，但其他方面相似。医疗大麻州注册中心通常报告消费者、临床医生和销售数据，而不是健康和安全结果。需要更全面和统一的医疗大麻公共卫生监测。（2024 年；114（S8）：S685-S693。https://doi.org/10.2105/AJPH.2024.307728）。
